Lingmin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lingmin Zhang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Mingxin Zhang
Department of Gastroenterology, The First Affiliated Hospital of Xi’an Medical University, Xi’an, China
19 shared publications Li Wang
Department of Scientific Research, The Affiliated Hospital of Xi’an Medical University, Xi’an, China
5 shared publications- Manli Cui
Department of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, China
5 shared publications - Suna Zhou
School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China
5 shared publications Manli Cui
Department of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China; Engineering Research Center of Shaanxi Universities for Innovative Services of Chronic Disease Prevention and Control and Transformation of Nutritional Functional Food, Xi'an, Shaanxi, 710077, China
4 shared publications- Honglin Yan
Xian Med Univ, Affiliated Hosp 1, Dept Gastroenterol, 48 Feng Hao West Rd, Xian 710077, Peoples R China
3 shared publications
Latest Publications
- 10 April 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 361, 151921
Regulation of SLC7A11 by METTL3 induces cisplatin resistance in esophageal cancer
- 10 April 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 361, 151921
Regulation of SLC7A11 by METTL3 induces cisplatin resistance in esophageal cancer
- Open Access
- 3 May 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2875-2883
First-line treatment options for advanced gastric/gastroesophageal junction cancer patients with PD-L1-positive: a systematic review and meta-analysis
Background: Lately, many trials have paid much attention on the oncological outcomes of immunotherapy combined with chemotherapy as a first-line treatment. The authors perform a systematic meta-analysis to assess the efficacy and safety of programmed death 1 inhibitor plus chemotherapy for first-line treatment in advanced gastric/gastroesophageal junction cancer. Materials and methods: Literature search through major databases in English and Chinese: PubMed, Embase, Cochrane library, web of Science and CNKI updated on 10 March 2023. Randomized controlled trials were selected to investigate chemotherapy plus programmed death 1 inhibitor versus chemotherapy. Results: A total of 7 randomised controlled trials including 5788 participants were included. The overall survival (hazard ratio=0.79;95% CI: 0.74–0.85, PPPPPP<0.01). Conclusion: Programmed death 1 inhibitors plus chemotherapy have significant antitumour activity compared to chemotherapy alone. However, it is riskier in terms of toxicity than chemotherapy. The authors recommend programmed death 1 inhibitors plus chemotherapy as the optimal treatment regimen for patients with positive programmed death ligand 1 expression, in Asia, male and less than 65 years of age. More well-designed studies are needed to investigate the efficacy and safety of different immune plus chemotherapy drug doses and regimens.
- 3 May 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2875-2883
Open AccessFirst-line treatment options for advanced gastric/gastroesophageal junction cancer patients with PD-L1-positive: a systematic review and meta-analysis
Background: Lately, many trials have paid much attention on the oncological outcomes of immunotherapy combined with chemotherapy as a first-line treatment. The authors perform a systematic meta-analysis to assess the efficacy and safety of programmed death 1 inhibitor plus chemotherapy for first-line treatment in advanced gastric/gastroesophageal junction cancer. Materials and methods: Literature search through major databases in English and Chinese: PubMed, Embase, Cochrane library, web of Science and CNKI updated on 10 March 2023. Randomized controlled trials were selected to investigate chemotherapy plus programmed death 1 inhibitor versus chemotherapy. Results: A total of 7 randomised controlled trials including 5788 participants were included. The overall survival (hazard ratio=0.79;95% CI: 0.74–0.85, PPPPPP<0.01). Conclusion: Programmed death 1 inhibitors plus chemotherapy have significant antitumour activity compared to chemotherapy alone. However, it is riskier in terms of toxicity than chemotherapy. The authors recommend programmed death 1 inhibitors plus chemotherapy as the optimal treatment regimen for patients with positive programmed death ligand 1 expression, in Asia, male and less than 65 years of age. More well-designed studies are needed to investigate the efficacy and safety of different immune plus chemotherapy drug doses and regimens.
- Open Access
- 10 August 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-9
Recent advances of m6A methylation modification in esophageal squamous cell carcinoma
In recent years, with the development of RNA sequencing technology and bioinformatics methods, the epigenetic modification of RNA based on N6-methyladenosine (m6A) has gradually become a research hotspot in the field of bioscience. m6A is the most abundant internal modification in eukaryotic messenger RNAs (mRNAs). m6A methylation modification can dynamically and reversibly regulate RNA transport, localization, translation and degradation through the interaction of methyltransferase, demethylase and reading protein. m6A methylation can regulate the expression of proto-oncogenes and tumor suppressor genes at the epigenetic modification level to affect tumor occurrence and metastasis. The morbidity and mortality of esophageal cancer (EC) are still high worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common tissue subtype of EC. This article reviews the related concepts, biological functions and recent advances of m6A methylation in ESCC, and looks forward to the prospect of m6A methylation as a new diagnostic biomarker and potential therapeutic target for ESCC.
- 10 August 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-9
Open AccessRecent advances of m6A methylation modification in esophageal squamous cell carcinoma
In recent years, with the development of RNA sequencing technology and bioinformatics methods, the epigenetic modification of RNA based on N6-methyladenosine (m6A) has gradually become a research hotspot in the field of bioscience. m6A is the most abundant internal modification in eukaryotic messenger RNAs (mRNAs). m6A methylation modification can dynamically and reversibly regulate RNA transport, localization, translation and degradation through the interaction of methyltransferase, demethylase and reading protein. m6A methylation can regulate the expression of proto-oncogenes and tumor suppressor genes at the epigenetic modification level to affect tumor occurrence and metastasis. The morbidity and mortality of esophageal cancer (EC) are still high worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common tissue subtype of EC. This article reviews the related concepts, biological functions and recent advances of m6A methylation in ESCC, and looks forward to the prospect of m6A methylation as a new diagnostic biomarker and potential therapeutic target for ESCC.
- Open Access
- 1 August 2021
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 12 (4) , 1241-1254
Construction and evaluation of prognostic models for esophageal cancer patients with distant and non-distant metastases: providing a reference process for clinical diagnosis and treatment
Background: Although the current treatment for esophageal cancer has great technological progress, the 5-year survival rate of patients is not optimistic. About 70% of patients with esophageal cancer are at an advanced stage at first diagnosis. These patients are prone to distant metastasis, and the prognosis is poor. Therefore, understanding the risk factors for distant metastasis in patients with esophageal cancer, combined with the prognosis of the patient, can aid in choosing the optimal diagnosis and treatment plan. Ultimately, it will improve the patient’s survival time and quality of life. This research aims to construct a model for the risk assessment of distant metastasis in patients with esophageal cancer and prognostic models for patients with distant and non-distant metastases. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to select patients with esophageal cancer from 2010 to 2015. The optimal cutoff point was selected for the age and tumor size variables using X-tile. The nomogram was constructed using R software (The R Foundation for Statistical Computing). Results: Gender, grade, T stage, N stage, and tumor size were independent risk factors associated with distant metastasis in patients with esophageal cancer. The concordance index (C-index) of the nomogram prediction model for whether the patient will have distant metastasis was 0.609. Age, grade, T stage, N stage, and tumor size were independent risk factors affecting the prognosis without distant metastasis. The C-index of the nomogram prediction model for patients with distant metastases was 0.590. Age and T stage were independent risk factors affecting the prognosis of patients with distant metastases. The C-index of the nomogram prediction model was 0.543. The combination of radiotherapy, chemotherapy, and primary surgery yielded the best overall survival for both patients with distant metastases and patients with non-distant metastases. Conclusions: A comprehensive assessment of the risk of distant metastasis in patients with esophageal cancer, combined with prognosis prediction, is necessary to provide patients with a reasonable treatment plan.
- 1 August 2021
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 12 (4) , 1241-1254
Open AccessConstruction and evaluation of prognostic models for esophageal cancer patients with distant and non-distant metastases: providing a reference process for clinical diagnosis and treatment
Background: Although the current treatment for esophageal cancer has great technological progress, the 5-year survival rate of patients is not optimistic. About 70% of patients with esophageal cancer are at an advanced stage at first diagnosis. These patients are prone to distant metastasis, and the prognosis is poor. Therefore, understanding the risk factors for distant metastasis in patients with esophageal cancer, combined with the prognosis of the patient, can aid in choosing the optimal diagnosis and treatment plan. Ultimately, it will improve the patient’s survival time and quality of life. This research aims to construct a model for the risk assessment of distant metastasis in patients with esophageal cancer and prognostic models for patients with distant and non-distant metastases. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to select patients with esophageal cancer from 2010 to 2015. The optimal cutoff point was selected for the age and tumor size variables using X-tile. The nomogram was constructed using R software (The R Foundation for Statistical Computing). Results: Gender, grade, T stage, N stage, and tumor size were independent risk factors associated with distant metastasis in patients with esophageal cancer. The concordance index (C-index) of the nomogram prediction model for whether the patient will have distant metastasis was 0.609. Age, grade, T stage, N stage, and tumor size were independent risk factors affecting the prognosis without distant metastasis. The C-index of the nomogram prediction model for patients with distant metastases was 0.590. Age and T stage were independent risk factors affecting the prognosis of patients with distant metastases. The C-index of the nomogram prediction model was 0.543. The combination of radiotherapy, chemotherapy, and primary surgery yielded the best overall survival for both patients with distant metastases and patients with non-distant metastases. Conclusions: A comprehensive assessment of the risk of distant metastasis in patients with esophageal cancer, combined with prognosis prediction, is necessary to provide patients with a reasonable treatment plan.
- Open Access
- 17 February 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-11
Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer
Background: Platinum-based chemotherapy is a mainstay for treating esophageal cancer patients. In this manuscript, we have provided clues for influence of platinum on overall m6A level and further investigated the potential regulatory mechanism. Methods: qRT-PCR was used to measure SNHG3 and miR-186-5p expression; ELISA and western blot were used to measure the expression of METTL3. CCK8 was used to measure the cell proliferation rate. Caspase 3/7 activity was used to measure the apoptosis rate. Dual luciferase reporter gene assay and RNA pull down assay were used to investigate the potential crosstalk between miR-186-5p and SNHG3; and miR-186-5p and METTL3. Results: m6A level was increased when treated with platinum (CDDP, CPB and L-OHP). Besides, SNHG3 expression was induced and miR-186-5p expression was suppressed by platinum. Furthermore, SNHG3 could promote the m6A level, however miR-186-5p inhibited the m6A level through targeting METTL3. SNHG3 interacts with miR-186-5p to negatively regulate the expression of miR-186-5p; and miR-186-5p might bind to the 3′UTR of METTL3 to regulate its expression. Conclusion: Platinum can increase the overall m6A level of esophageal cancer. SNHG3/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. Our manuscript has provided clues that regulating m6A level might be a novel way to enhance the platinum efficacy.
- 17 February 2021
- Published by Springer Nature in Cancer Cell International
- Vol. 21 (1) , 1-11
Open AccessTargeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer
Background: Platinum-based chemotherapy is a mainstay for treating esophageal cancer patients. In this manuscript, we have provided clues for influence of platinum on overall m6A level and further investigated the potential regulatory mechanism. Methods: qRT-PCR was used to measure SNHG3 and miR-186-5p expression; ELISA and western blot were used to measure the expression of METTL3. CCK8 was used to measure the cell proliferation rate. Caspase 3/7 activity was used to measure the apoptosis rate. Dual luciferase reporter gene assay and RNA pull down assay were used to investigate the potential crosstalk between miR-186-5p and SNHG3; and miR-186-5p and METTL3. Results: m6A level was increased when treated with platinum (CDDP, CPB and L-OHP). Besides, SNHG3 expression was induced and miR-186-5p expression was suppressed by platinum. Furthermore, SNHG3 could promote the m6A level, however miR-186-5p inhibited the m6A level through targeting METTL3. SNHG3 interacts with miR-186-5p to negatively regulate the expression of miR-186-5p; and miR-186-5p might bind to the 3′UTR of METTL3 to regulate its expression. Conclusion: Platinum can increase the overall m6A level of esophageal cancer. SNHG3/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. Our manuscript has provided clues that regulating m6A level might be a novel way to enhance the platinum efficacy.
- Open Access
- 3 August 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-9
Circular RNAs and esophageal cancer
As a new kind of RNA, circular RNA (circRNA) is a endogenous non-coding RNA with circular structure, which has the characteristics of universality, stability, conservatism and specificity. CircRNA can specifically bind to microRNAs (miRNAs) in the form of competitive endogenous RNA, thus directly or indirectly regulating the expression of related genes. In addition to the role of sponge, circRNA also regulates parental gene expression, transcriptional translation and protein modification; and it can be used as a biomarker to develop potential diagnosis and treatment methods and evaluate prognosis. Due to changes in dietary habits and genetic factors, the morbidity and mortality of esophageal cancer (EC) in the world are still high, and are prone to early metastasis. Although the diagnosis and treatment techniques have been improved in recent years, the early diagnosis of EC is not common, and the 5-year survival rate of patients is still very low. This article reviews the function and significance of circRNA and discusses the research progress of circRNA as biomarkers in EC.
- 3 August 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-9
Open AccessCircular RNAs and esophageal cancer
As a new kind of RNA, circular RNA (circRNA) is a endogenous non-coding RNA with circular structure, which has the characteristics of universality, stability, conservatism and specificity. CircRNA can specifically bind to microRNAs (miRNAs) in the form of competitive endogenous RNA, thus directly or indirectly regulating the expression of related genes. In addition to the role of sponge, circRNA also regulates parental gene expression, transcriptional translation and protein modification; and it can be used as a biomarker to develop potential diagnosis and treatment methods and evaluate prognosis. Due to changes in dietary habits and genetic factors, the morbidity and mortality of esophageal cancer (EC) in the world are still high, and are prone to early metastasis. Although the diagnosis and treatment techniques have been improved in recent years, the early diagnosis of EC is not common, and the 5-year survival rate of patients is still very low. This article reviews the function and significance of circRNA and discusses the research progress of circRNA as biomarkers in EC.
- 28 August 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (12) , 19345-19357
Linc‐PINT acted as a tumor suppressor by sponging miR‐543 and miR‐576‐5p in esophageal cancer
This manuscript aimed to investigate linc‐PINT's role as a tumor suppressor and its downstream microRNAs (miRNAs) in esophageal cancer. Log‐rank, Cox, and nomogram were used for survival analysis. Quantitative real‐time polymerase chain reaction was used to evaluate the expression. Cell counting kit‐8 was used for proliferation tests. As for in vivo experiments, low expression of linc‐PINT was associated with better prognosis; besides, the nomogram indicated that linc‐PINT, miR‐543, and miR‐576‐5p served well in predicting the survival rate. As for the in vitro experiments, linc‐PINT could directly regulate miR‐543 and miR‐576‐5p to inhibit the proliferation of Eca‐109 cell line. In conclusion, linc‐PINT–miR‐543/miR‐576‐5p pathway could predict the prognosis and provide novel therapeutic targets for esophageal cancer.
- 28 August 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (12) , 19345-19357
Linc‐PINT acted as a tumor suppressor by sponging miR‐543 and miR‐576‐5p in esophageal cancer
This manuscript aimed to investigate linc‐PINT's role as a tumor suppressor and its downstream microRNAs (miRNAs) in esophageal cancer. Log‐rank, Cox, and nomogram were used for survival analysis. Quantitative real‐time polymerase chain reaction was used to evaluate the expression. Cell counting kit‐8 was used for proliferation tests. As for in vivo experiments, low expression of linc‐PINT was associated with better prognosis; besides, the nomogram indicated that linc‐PINT, miR‐543, and miR‐576‐5p served well in predicting the survival rate. As for the in vitro experiments, linc‐PINT could directly regulate miR‐543 and miR‐576‐5p to inhibit the proliferation of Eca‐109 cell line. In conclusion, linc‐PINT–miR‐543/miR‐576‐5p pathway could predict the prognosis and provide novel therapeutic targets for esophageal cancer.
- 1 January 2019
- Published by Begell House Inc. Publishers in Critical Reviews™ in Eukaryotic Gene Expression
- Vol. 29 (2) , 151-160
Function, Significance, and Regulation of Rap1b in Malignancy
Ras-associated protein 1(Rap1) is a member of the RAS family of small G proteins and regulates several signal pathways involved in carcinogenesis. Rap1 consists of two highly homologous isoforms, Rap1a and Rap1b. Increasing data suggest that the deregulated activation of Rap1b is involved in a spectrum of malignancies. Accumulating evidence also indicates effects of Rap1b on cell proliferation, metastasis, angiogenesis, and treatment resistance. Rap1b overexpresses in many tumors and has prognostic values, which are regulated by A2br, miRNAs, and other upstream effectors. This article aims to review research progress in function, significance, and regulation of Rap1b in malignancy.
- 1 January 2019
- Published by Begell House Inc. Publishers in Critical Reviews™ in Eukaryotic Gene Expression
- Vol. 29 (2) , 151-160
Function, Significance, and Regulation of Rap1b in Malignancy
Ras-associated protein 1(Rap1) is a member of the RAS family of small G proteins and regulates several signal pathways involved in carcinogenesis. Rap1 consists of two highly homologous isoforms, Rap1a and Rap1b. Increasing data suggest that the deregulated activation of Rap1b is involved in a spectrum of malignancies. Accumulating evidence also indicates effects of Rap1b on cell proliferation, metastasis, angiogenesis, and treatment resistance. Rap1b overexpresses in many tumors and has prognostic values, which are regulated by A2br, miRNAs, and other upstream effectors. This article aims to review research progress in function, significance, and regulation of Rap1b in malignancy.
- 1 November 2017
- Published by Mineralogical Society of America in American Mineralogist: Journal of Earth and Planetary Materials
- Vol. 102 (11) , 2268-2283
Unusual replacement of Fe-Ti oxides by rutile during retrogression in amphibolite-hosted veins (Dabie UHP terrane): A mineralogical record of fluid-induced oxidation processes in exhumed UHP slabs
The replacement of rutile by Fe-Ti oxides is a common phenomenon during the retrogression of eclogites. Here, we report an unusual case regarding the replacement of Fe-Ti oxides by rutile during greenschist-facies metamorphic overprinting of veins in amphibolites (retrograded eclogites) from the Dabie ultrahigh-pressure (UHP) terrane, eastern China. The veins mainly consist of plagioclase, Fe-Ti oxides, and quartz, which crystallized from a Ti-rich amphibolite-facies fluid that formed during exhumation of the eclogites. Two types of textures involving the replacement of Fe-Ti oxides by rutile are recognized in the veins: (1) the first type is characterized by the development of rutile coronas (Rt-C) and other silicates (high-Fe epidote, muscovite, and chlorite) around the external boundaries of the Fe-Ti oxide grains, and (2) the second type is characterized by the formation of symplectitic intergrowths of rutile (Rt-S) and magnetite after exsolved hemo-ilmenite (H-Ilm) lamellae in the Fe-Ti oxides. The micro-textures, mineral assemblages, and Zr-in-rutile thermometry indicate that both replacement reactions involved mineral re-equilibration processes in the presence of an infiltrating fluid phase at ~476–515 °C, taking place by an interface-coupled dissolution-precipitation mechanism. Thermodynamic modeling reveals that both replacement reactions occurred during oxidation processes under relatively high-oxygen fugacity (fO2) conditions, approximately 2.5–4.5 logfO2 units higher than the fayalite-magnetite-quartz (FMQ) reference buffer. In situ Sr isotopic analyses of epidote (Ep-C) coexisting with the Rt-C suggest that the infiltrating fluid involved in the greenschist-facies replace- ment reactions was externally derived from the surrounding granitic gneisses (the wall rocks of the amphibolites). Compared with the rutile in the UHP eclogites (Rt-E) and amphibolites (Rt-A), the Rt-C is characterized by distinctly lower contents of Nb (1580 ppm). These results provide a geochemical fingerprint for distinguishing the low-pressure (LP) rutile from relic high-grade phases in retrograded HP-UHP rocks. Our results reveal that rutile can form during LP retrograde stage in UHP rocks by high-fO2 fluid-induced replacement reactions. The unusual replacements of Fe-Ti oxides by rutile-bearing assemblages during retrogression provide important constraints on fluid-mineral reactions and fO2 variations in exhumed UHP slabs.
- 1 November 2017
- Published by Mineralogical Society of America in American Mineralogist: Journal of Earth and Planetary Materials
- Vol. 102 (11) , 2268-2283
Unusual replacement of Fe-Ti oxides by rutile during retrogression in amphibolite-hosted veins (Dabie UHP terrane): A mineralogical record of fluid-induced oxidation processes in exhumed UHP slabs
The replacement of rutile by Fe-Ti oxides is a common phenomenon during the retrogression of eclogites. Here, we report an unusual case regarding the replacement of Fe-Ti oxides by rutile during greenschist-facies metamorphic overprinting of veins in amphibolites (retrograded eclogites) from the Dabie ultrahigh-pressure (UHP) terrane, eastern China. The veins mainly consist of plagioclase, Fe-Ti oxides, and quartz, which crystallized from a Ti-rich amphibolite-facies fluid that formed during exhumation of the eclogites. Two types of textures involving the replacement of Fe-Ti oxides by rutile are recognized in the veins: (1) the first type is characterized by the development of rutile coronas (Rt-C) and other silicates (high-Fe epidote, muscovite, and chlorite) around the external boundaries of the Fe-Ti oxide grains, and (2) the second type is characterized by the formation of symplectitic intergrowths of rutile (Rt-S) and magnetite after exsolved hemo-ilmenite (H-Ilm) lamellae in the Fe-Ti oxides. The micro-textures, mineral assemblages, and Zr-in-rutile thermometry indicate that both replacement reactions involved mineral re-equilibration processes in the presence of an infiltrating fluid phase at ~476–515 °C, taking place by an interface-coupled dissolution-precipitation mechanism. Thermodynamic modeling reveals that both replacement reactions occurred during oxidation processes under relatively high-oxygen fugacity (fO2) conditions, approximately 2.5–4.5 logfO2 units higher than the fayalite-magnetite-quartz (FMQ) reference buffer. In situ Sr isotopic analyses of epidote (Ep-C) coexisting with the Rt-C suggest that the infiltrating fluid involved in the greenschist-facies replace- ment reactions was externally derived from the surrounding granitic gneisses (the wall rocks of the amphibolites). Compared with the rutile in the UHP eclogites (Rt-E) and amphibolites (Rt-A), the Rt-C is characterized by distinctly lower contents of Nb (1580 ppm). These results provide a geochemical fingerprint for distinguishing the low-pressure (LP) rutile from relic high-grade phases in retrograded HP-UHP rocks. Our results reveal that rutile can form during LP retrograde stage in UHP rocks by high-fO2 fluid-induced replacement reactions. The unusual replacements of Fe-Ti oxides by rutile-bearing assemblages during retrogression provide important constraints on fluid-mineral reactions and fO2 variations in exhumed UHP slabs.